BIIB's BG-12 Review Period Extended - Analyst Blog NASDAQ Meanwhile, Biogen and partner Abbott Labs ( ABT ) moved another MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010, with results due in 2014. Daclizumab is being evaluated as a once-monthly or bi-weekly subcutaneous ... Through 2021, The Number of Disease-Modifying Therapies Approved for The ... |
